Exploring how mTOR inhibitors can promote longevity and healthy aging
Novel longevity enhancing pathways regulated by mTOR
['FUNDING_R01'] · DREXEL UNIVERSITY · NIH-11078850
This study is looking at how a medication called rapamycin might help improve health as we age by keeping our stem cells healthy and preventing them from aging too quickly, which could lead to new ways to help people live better as they get older.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DREXEL UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11078850 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of mTOR inhibitors, specifically rapamycin, on age-related dysfunction and cellular senescence. By understanding how these inhibitors can enhance longevity and maintain stem cell health, the study aims to identify new targets for intervention and markers to monitor individual responses. The approach includes examining the role of the non-coding RNA H19 in preventing senescence and promoting pluripotency in stem cells. Patients may benefit from insights that could lead to safer and more effective aging interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults experiencing age-related dysfunction or diseases such as Alzheimer's.
Not a fit: Patients who are not experiencing age-related conditions or are younger than the target age group may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that promote healthy aging and potentially reverse age-related diseases.
How similar studies have performed: Previous research has shown promising results with mTOR inhibitors in promoting longevity, indicating that this approach has potential for success.
Where this research is happening
PHILADELPHIA, UNITED STATES
- DREXEL UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SELL, CHRISTIAN — DREXEL UNIVERSITY
- Study coordinator: SELL, CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: age associated disease, age associated disorder, age dependent disease, age dependent disorder